They didn't actually state the nature of the trial, but it would seem that they are not satisfied by the nature of the historical control data provided by the company. That maybe because it doesn't represent more modern treatment results.
But, I'm interested because of he possibility that the treatment does offer some patients the chance of cure by down staging the tumor sufficiently for surgical resection. That's quite important, but investors need to be aware it'll be a few years to getting an RCT done. So finding a way to get sufficient regulatory approvals that the company can get revenue earlier is important. It's a long haul, and it could go lower yet.
OSL Price at posting:
6.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)